Therefore, targeting these sites during early-stage PD may be useful in preventing the infiltration of pathology into the brain, whilst similar intervention during the later stages could be harnessed to slow disease progression by increasing the clearance of pathological ɑ-synuclein. The gene discussed is SNCA; the disease is Parkinson disease.